The GLP-1 Patent Thicket: Why One Drug Has Dozens of Patents

Here is a small fact about Ozempic: depending on who is counting, it is protected by 21 patents, or 19, or 39. The FDA’s Orange Book, which is the official list of patents attached to an approved drug, lists 21 for Ozempic, two of which cover the drug substance itself. Private patent trackers count about 39 U.S. drug patents for Ozempic, of which roughly 19 are still active. Two are about the molecule. The rest are about other stuff.

So if you typed “ozempic patent” into a search engine hoping for one expiry date, the plain answer is that there isn’t one. The core U.S. compound patent, US 8,129,343, runs to December 5, 2031. Novo Nordisk, in its 2025 Form 20-F, gives the U.S. compound expiry for Ozempic, Rybelsus and Wegovy as 2032. Secondary patents run to 2038, and one runs to 2041. The date a cheaper generic actually reaches American pharmacies is set by litigation settlements whose terms are confidential, and those settlements, according to Generic Guide, “point to generic entry around 2032.” The patent is not a single thing. It is a thicket.

How many patents a GLP-1 drug normally has

Ozempic is not unusual here. A JAMA study of GLP-1 receptor agonists found a median of 19.5 patents per product, with 54% of those patents covering delivery devices rather than active ingredients, and a median total expected protection of 18.3 years after FDA approval. Rybelsus, the pill version of semaglutide, has 15 U.S. drug patents filed between 2019 and 2026, 14 of them active. By the standards of its class, Ozempic’s 21 listed patents is sort of average.

The weird part is the ratio. More than half the patents on a typical GLP-1 drug are about the pen. The drug is the reason anyone buys the product, and most of the paperwork is about the plastic (which is, in fairness, the part you can hold).

The Ozempic patent that matters, and when it ends

The patent everyone means is the compound patent, the one that claims the molecule. It expires in 2026. Actually, no: it was originally due to expire in 2026, and then Novo Nordisk received a Patent Term Adjustment of 1,114 days and a Patent Term Extension of 1,040 days on its U.S. semaglutide drug substance patents (the first compensates for time spent at the patent office, the second for time spent getting the drug approved). That pushes the term to December 5, 2031, and Novo itself reports 2032 as the effective date. So the core patent ends about five years after it would have, under rules designed so that it would.

There is a second core patent, US 8,536,122, titled “Acylated GLP-1 compounds,” which protects Ozempic, Wegovy and Rybelsus and appears in four separate drug applications. Its principal commercial claim, claim 9, identifies Aib8,22, Arg34-GLP-1(7-37), which is the peptide backbone of semaglutide. That is the actual invention, written in a notation that only a few hundred people can read comfortably (and they all bill hourly).

Why a pen gets patents too

Then come the secondary patents, which is where the dates spread out. Three patents titled “GLP-1 compositions and uses thereof” cover Ozempic, Wegovy and Wegovy HD and expire August 24, 2038. A fourth with the same title, US 11,318,191, runs to February 17, 2041. “Semaglutide in medical therapy” covers Ozempic to October 10, 2038. “Semaglutide in cardiovascular conditions” runs to April 28, 2037. Trackers say Ozempic’s patents also include the injection pen, with expiries spread across 2031, 2034 and 2037.

And then, for instance, there are patents titled “Oral dosing of GLP-1 compounds,” expiring May 2, 2034, which trackers list as covering Ozempic and Rybelsus. There are also two patents on “solid compositions” of a GLP-1 agonist with an absorption enhancer called SNAC, expiring February 1, 2039, listed as covering Ozempic and Wegovy. Ozempic is a liquid in a pen. The facts available here do not settle why an oral-dosing patent sits under an injection (it may be how the trackers group patent families, or whatever), but it does give you a sense of how wide the fence is drawn.

The pen patents make sense from inside a drug company. An improvement to a dosing button is a real engineering change, and filing on it is cheap relative to what the drug earns. Here is an invented conversation, for illustration only: “We moved the dose counter two millimeters.” “File.” “It’s two millimeters.” “File twice.”

This matters because a device patent can outlive a molecule patent. Victoza, the older Novo drug liraglutide, has a device patent on its injection button running to September 2032 and a cardiovascular method-of-use patent running to January 2037, even though its compound patent is gone. A generic maker can copy the molecule freely and still get sued over the button.

Litigation, settlements, and the date nobody publishes

How does a generic actually get onto the American market, then? Not by waiting for every one of the 21 patents to lapse. A generic company files with the FDA, challenges the patents it thinks are invalid or not infringed, and the brand sues. Then, usually, everybody settles.

Novo Nordisk settled its U.S. Ozempic patent litigation with Alvogen, Rio Biopharmaceuticals, Sun Pharma, Dr. Reddy’s, Mylan, Zydus and Apotex. All of the settlement terms are confidential. Apotex has already received the first FDA tentative approval for a generic Ozempic, which, as the law firm Pearce IP puts it, means the product “meets all statutory and regulatory requirements for approval but cannot be marketed in the US because of patents or exclusivities.” The generic is finished. It is waiting on a contract.

The Victoza precedent shows how this plays out. Teva launched the first U.S. generic GLP-1, an authorized generic of Victoza, on June 24, 2024, under a settlement signed with Novo in 2019. The entry date was decided five years before it happened, privately, and it was not the date printed on any patent.

Everyone in this is behaving sensibly from where they sit. Novo is protecting the revenue that funds its next drug. The generic makers would rather have a certain launch date than a coin flip in court over 19 patents. The FDA lists what it is given (which is a job description, not a complaint). The fight is now repeating with Eli Lilly, which overtook Novo as the GLP-1 market leader by 2026 and sued 14 generic companies, including Sandoz and Dr. Reddy’s, in August 2026 over challenges to tirzepatide, whose compound patent runs to May 13, 2036.

Three ways to read the thicket

There are, roughly, three ways to read all this.

The first is that the patents are just inventions. Semaglutide works (the drug class has helped patients lose up to 20% of their body weight), and the pen, the formulations and the cardiovascular uses each took real work. On this reading, 21 patents means 21 things somebody figured out, and the 2038 expiries are simply what happens when you keep improving a product. It must be tiring to keep inventing useful refinements at exactly the moment the earlier ones start to expire, and presumably the timing is a coincidence.

The second is that the patents are bargaining chips. A patent that would probably lose in court is still worth something, because litigating it is slow and uncertain, and uncertainty is what a settlement buys. On this reading, the secondary patents aren’t really meant to last until 2038. They are meant to make 2032 feel like a good deal. Industry analysts describe the U.S. semaglutide market as protected by a thicket “through 2033,” which is later than the molecule and much earlier than the last patent, and is roughly what you would expect if the patents were mostly there to be traded.

The third reading is the least comfortable. The date that matters to patients and insurers, the day the price can actually fall, is not public law at all. It is a term in seven confidential contracts. You can read every patent, count them however you like, and still not know when generic Ozempic arrives in the U.S., because the answer was negotiated by the parties and the people paying for the drug were not among them. I don’t know what the settled dates are. Neither, officially, does anyone outside those rooms. Anyway, the patents are public and the date isn’t.

So Ozempic has 21 patents, or 19, or 39, and the one number a patient cares about is the one nobody gets to count. The only place where the count went to zero early was Canada, where the main patent lapsed in 2019 because Novo did not pay a maintenance fee of CAD $250, roughly $180.